Riding the Momentum! Successful Protocol Discussion Meeting Held for Onradivir Granules Phase III Trial in Pediatric Influenza A

Breakthrough! China's First-In-Class PB2-Targeting Antiviral Onradivir Tablets Approved for Market Launch, Pioneering New Era in Influenza Treatment!

Breakthrough! China’s First Single-Agent 3CL Inhibitor, Leiretavir Tablets, Granted Conditional Approval

Raynovent Announces Approval of Investigational New Drug (IND) Application of Category 1 Drug ZSP0678 for a New Indication

Dr. Chen Xiaoxin, Vice President of Raynovent was Invited to Attend CHBD Year-end Party - Shenzhen Station.